Siegfried Holding AG · SIX:SFZN

Siegfried — Investor Presentation (March 2024)

26 slides from Siegfried's investor presentation, March 2024

  1. Slide 1: Siegfried at a glance

    Siegfried at a glance

  2. Slide 2: About us

    About us Siegfried at a glance

  3. Slide 3: Siegfried at a glance – a globally leading CDMO

    Siegfried at a glance – a globally leading CDMO PRODUCTION OF HEADQUARTERED IN PUBLICLY LISTED Active Pharmaceutical Ingredients and Finished Dosage Forms Zofingen (CH) since 1973 NUMBER OF SITES GLOBALLY EXPAND GLOBAL REVENUE 2023 (CHF) GROWTH SINCE 2010 12 7 x API, 5x FDF thereof 2 in Spain >1.2bn

  4. Slide 4: Our offering along the value chain

    Our offering along the value chain We offer integrated supply of APIs and finished products. Integration Drug Substances (DS) DS & DP Drug Products (DP) Drug Process Dosage Clinical Commercial Marketing discovery development Intermediates API formulation supplies production & distribution Bringing t

  5. Slide 5: Our production network offers a unique combination of flexibility and integration

    Our production network offers a unique combination of flexibility and integration for both, innovative an generic products Zofingen Switzerland 1 DS Development & Manufacturing Pennsville USA 2 DS Manufacturing 7 Hal Far Malta 3 DP Manufacturing 1 6 Irvine USA 4 8 DP Manufacturing 4 Nantong China 5

  6. Slide 6: Our mission, Our vision, Our values

    Our mission Our vision Our values Siegfried at a glance

  7. Slide 7: Our mission: We do matter to customers, patients and society

    Our mission: We do matter to customers, patients and society «With mastery of science and technology, we take the precious innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide» 7

  8. Slide 8: Our vision: We aim for industry leadership

    Our vision: We aim for industry leadership «Siegfried is the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space – because… …we are the strongest team running the most competitive network» 8

  9. Slide 9: Our values: We strive for outstanding performance

    Our values: We strive for outstanding performance Excellence «Our values and leadership principles are «We excel in everything we do» the basis to build the strongest team in the industry» Passion «We deeply care ybout what we do and how we do it» Integrity «We act responsibly, reliably, respectfull

  10. Slide 10: Our leadership values are the basis to build the strongest team in the industry

    Our leadership values are the basis to build the strongest team in the industry Foster Empower customer people intimacy Deliver quality Ensure and value performance Focus on Lead and customers develop people Foster innovation Drive business Excellence and excellence growth Passion Manage Lead and In

  11. Slide 11: Our history

    Our history Siegfried at a glance

  12. Slide 12: Our history

    Our history 1873 Pharmacist Samuel Benoni Siegfried founded a comapy with 12 employees as a supplier to pharmacies 1973 Quotation on the Swiss Stock Exchange (SWX) in Basel 1991 2005 Focus on custom Akquisition der development and Penick Corporation manufacturing in New Jersey (USA) 2001 2007 Buildi

  13. Slide 13: Our history

    Our history 2012 Acquisition of Alliance Medical Products (AMP) in 2021 Irvine (CA, USA) Acquisition of two pharmaceutical production sites from Novartis in Barberà del Vallès and El Masnou (ES) 2023 Acquisition of a 2014 majority stake in Acquisition of Hameln Pharma DiNAMIQS, a in Hameln (DE) Swis

  14. Slide 14: Our management

    Our managment Siegfried at a glance

  15. Slide 15: Management – Board of Directors

    Management – Board of Directors Dr. Andreas Casutt CHAIRMAN Dr. Martin Schmid Dr. Alexandra Brand Dr. Beat Walti Prof. Dr. Wolfram Carius Isabelle Welton Elodie Carr-Cingari 15

  16. Slide 16: Management – Executive Committee

    Management – Executive Committee Dr. Wolfgang Wienand CHIEF EXECUTIVE OFFICER Dr. Jürgen Roos CHIEF SCIENTIFIC OFFICER Dr. Reto Suter CHIEF FINANCIAL OFFICER Marianne Späne CHIEF BUSINESS OFFICER DRUG SUBSTANCES AND DRUG PRODUCTS Marcel Imwinkelried CHIEF OPERATING OFFICER DRUG PRODUCTS Irene Wosgie

  17. Slide 17: Our business model

    Our business model Siegfried at a glance

  18. Slide 18: Drug Substances / Drug Products overview

    Overview Drug Substances APIs, intermediates Chemical controlled substances Chemical process procuction development Pharmaceutical Pharmaceutical development Solid dosage forms production services (including capsules for inhalation) Semi-solid dosage forms (ophthalmic ointments) Liquid dosage forms

  19. Slide 19: Our financials

    Our financials Siegfried at a glance

  20. Slide 20: Net sales

    Net sales Net sales split 2023 CHF million 2023 2022 Change Drug Substances 860.0 753.7 +14.1% (+16.8% in LC) Drug Products 411.5 475.8 -13.5% (-10.4% in LC) Total 1 271.5 1 229.5 +3.4% (+6.3% in LC) 32.4% 67.6% Drug Products Drug Substances 20

  21. Slide 21: Business development

    Business development Net sales (in million CHF) 1229.5 1271.5 1102.4 833.5 845.1 2019 2020 2021 2022 2023 21

  22. Slide 22: Business development – Share Price Development

    Business development ll Share Price Development BR from January 1, 2019, to December 31, 2023 SFZN SIQ |g ale ale ala alR wlan awn lo als mio als ais 38 Bis ais ais alg 1000 : : : 1 am 800 600 400 200 31.12 31.12 31.12 31.12 31.12 31.12 2019 2020 2021 2022 2023 @ Siegfried esp 2 a Siegfried

  23. Slide 23: Sustainability

    Sustainability Siegfried at a glance

  24. Slide 24: We do not only think about tomorrow, but far beyond

    We do not only think about tomorrow, but far beyond Siegfried started its Cross-functional Commitment: ESG journey years ago: ESG Governance Board Siegfried’s carbon › Code of Business Conduct sponsored by CEO and footprint to be reduced › Global Quality Policy supervised by BoD by 50% until 2030 ›

  25. Slide 25: Our ambitions to be an ESG leader in the CDMO market

    Our ambitions to be an ESG leader in the CDMO market Steps Energy Renewable Lost time Carbon footprint towards our target electricity accidents commitment3 ambition -10% 71% -11% -50% Target achieved: total energy 71% of our electricity comes Lost time injuries rate was reduced Carbon footprint to b

  26. Slide 26: Contact us

    CONTACT US Head Office Siegfried AG Untere Bruehlstrasse 4 4800 Zofingen Switzerland Tel. +41 62 746 11 11 info@siegfried.ch www.siegfried.ch 26

Siegfried Holding — Investor Presentation (March 2024) on 6ix